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Abstract
Introduction: Most HIV-positive persons in sub-Saharan Africa initiate antiretroviral therapy (ART) with advanced infection (late
ART initiation). Intervening on the drivers of late ART initiation is a critical step towards achieving the full potential of HIV
treatment scale-up. This study aimed to identify modifiable factors associated with late ART initiation in Ethiopia.
Methods: From 2012 to 2013, Ethiopian adults (n1180) were interviewed within two weeks of ART initiation. Interview
data were merged with HIV care histories to assess correlates of late ART initiation (CD4 count B150 cells/mL or World Health
Organization Stage IV).
Results: The median CD4 count at enrolment in HIV care was 263 cells/mL (interquartile range (IQR): 140 to 390) and 212 cells/mL
(IQR: 119 to 288) at ART initiation. Overall, 31.2% of participants initiated ART late, of whom 85.1% already had advanced HIV
disease at enrolment. Factors associated with higher odds of late ART initiation included male sex (vs. non-pregnant females;
adjusted odds ratio (aOR): 2.02; 95% CI: 1.50 to 2.73), high levels of psychological distress (vs. low/none, aOR: 1.96; 95% CI: 1.34
to 2.87), perceived communication barriers with providers (aOR: 2.42, 95% CI: 1.24 to 4.75), diagnosis via provider initiated
testing (vs. voluntary counselling and testing, aOR: 1.47, 95% CI: 1.07 to 2.04), tuberculosis (TB) treatment prior to ART initiation
(aOR: 2.16, 95% CI: 1.43 to 3.25) and a gap in care of six months or more prior to ART initiation (aOR: 2.02, 95% CI: 1.10 to 3.72).
Testing because of partner illness/death (aOR: 0.64, 95% CI: 0.42 to 0.95) was associated with lower odds of late ART initiation.
Conclusions: Programmatic initiatives promoting earlier diagnosis, engagement in pre-ART care, and integration of TB and
HIV treatments may facilitate earlier ART initiation. Men and those experiencing psychological distress may also benefit from
targeted support prior to ART initiation.
Keywords: HIV-positive adults; antiretroviral therapy initiation; tuberculosis treatment; Ethiopia; antiretroviral therapy
guidelines; implementation science.
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Introduction
Although HIV care services have been increasingly scaled
up [1], most HIV-positive persons in sub-Saharan Africa start
treatment only after developing advanced infection, which
leads to high earlymortality [2], complex and expensive clinical
management [3], blunted immune response [4] and missed
opportunities to prevent HIV transmission [5]. The problem of
late antiretroviral therapy (ART) initiation in sub-Saharan
Africa has improved only slightly since the start of HIV scale-
up in the region [6,7], making it important to identify its deter-
minants, as well as necessary programmatic adjustments and
policy changes.
Studies of factors associated with advanced HIV infection prior
to ART initiation (i.e. at diagnosis and/or presentation to care)
in sub-Saharan Africa have found that sex, pregnancy, age,
family composition, living arrangements, education level, em-
ployment status, competing priorities, disclosure status, emo-
tional health and alcohol use were important correlates [813].
Patients’ perceptions of stigma, medication side effects and
healthcare access barriers may also contribute [8,10]. Demo-
graphic and clinical factors associated with a higher likelihood of
advanced HIV disease at ART initiation have included male sex,
being already beyond the point of ART eligibility at the time of
enrolment into HIV care, TB treatment at ART initiation and a
]12 month gap in care between enrolment and ART initiation
[7,14]. A qualitative study from Uganda additionally reported
patient concerns about stigma, lack of confidentiality, low
social support and misconceptions about ART as barriers to ART
initiation [15]. However, most studies have not examined factors
beyond those routinely collected in HIVclinical records or the role
of the pre-ART phase of care, limiting the ability to inform the
development of interventions.
Ethiopia, with an estimated HIV prevalence among adults of
1.3% (590,000 persons) and 4.2% in urban areas [1,16], began
scaling up comprehensive HIV services (including ART) in 2005.
In 2012, however, only 68% of adult Ethiopians eligible for ART
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were receiving it [1]. In order to help maximize the individual
and public health benefit from the treatment eligibility guide-
line expansion [17], the present study was designed to identify
the major drivers of late ART initiation, particularly those that
are amenable to intervention.
Methods
Study setting
We enrolled 1180 patients initiating ARTat six HIV clinical care
sites in the Oromia region of Ethiopia, and part of the
Ethiopian National ART Program, under the jurisdiction of the
Oromia Regional Health Bureau. The combined catchment
areas of these clinics cover 9.3 million people, with back-
ground HIV prevalence estimates ranging from 3.2 to 11.5%,
according to antenatal clinic (ANC) data at the sites. The clinics
have been supported by the Ethiopian Ministry of Health
with technical assistance from ICAP at Columbia University
since 2005, via funding from the President’s Emergency Plan
for AIDS Relief. All six sites are secondary health facilities
in urban areas, with on-site CD4 testing and ART pharma-
cies. All offer voluntary counselling and testing (VCT), conduct
provider initiated counselling and testing (PITC) and have
ANC and labour and delivery wards. In January 2013, during
the course of this study, the national guidelines for ART
initiation were expanded from World Health Organization
(WHO) Stage IV or CD4 count B200 cells/mL or WHO Stage
III with CD4 B350 cells/mL to include all patients with
CD4 B350 cells/mL.
Participant recruitment and data collection
Interviews
All non-institutionalized patients aged 18 years and older
initiating ART between June 2012 and April 2013 were eligible
for inclusion in the study. Such persons were referred by
providers to the study staff on the day of ART initiation. Study
staff administered the structured questionnaire (lasting 45 to
60 minutes) with questions related to psychosocial factors
and HIVcare.The interviewswere conductedwithin twoweeks
of the day of ART initiation, and participants were given a
snack and money for transportation home from the clinic
(20 Ethiopian birr, or approximately 1 USD). Among the eligible
patients referred to the study, 95% consented and completed
the interview.
Routine clinical information
Data obtained from patients at the time of HIV care enrolment
and each subsequent clinic visit were recorded on national
forms. In accordance with routine clinic procedures, clerks
entered medical chart data into electronic databases. Assess-
ments of data entry completeness and accuracy were done
regularly. Interview data were linked with clinic medical re-
cords for the period between HIV care enrolment and ART
initiation and then de-identified for analysis.
Measures
Outcome
Advanced HIV infection at ART initiation was defined as having
a CD4 count B150 cells/mL or WHO Stage IV. CD4 count
or WHO stage at ART initiation included those measurements
taken three months before or one month after ART initiation.
In instances where CD4 count or WHO stage were missing
in the above window, we used the highest stage preceding
ART initiation and any prior CD4 count B150 cells/mL.
Psychosocial variables
Questionnaire design and variable selection were guided
by the framework of health service use developed by Aday
and Andersen [18]. Predisposing factors (i.e. pre-existing pro-
pensity to access care) examined included sex, age, education,
relationship status, having ever had children, alcohol use,
psychological distress, enacted and internalized stigma,
and history of holy water use for HIV. Alcohol use frequency
was divided into high (at least twice a week), moderate
(at least monthly) and low/none (never or not in the last
three months). Psychological distress was assessed through
the Kessler-10 scale, with three categories of distress: high
(score of 30 to 50), mild/moderate (20 to 29) and low/none
(10 to 19) [19]. Internalized and enacted stigma measures
(alpha0.99 with statements such as ‘‘you felt completely
worthless,’’ and alpha0.94 with statements such as ‘‘some-
one scolded you’’) had answer options ranging from ‘‘most of
the time’’ to ‘‘never’’ and were drawn from the instrument
developed by Holzemer et al. [20]. For analysis, average scores
on internalized stigma were grouped into tertiles and those
on enacted stigma into ‘‘any stigma’’ or ‘‘none,’’ based on the
respective score distributions. We also examined beliefs
related to ART through a set of 10 items (alpha0.74),
for example, ‘‘AIDS no longer kills everyone because of the
ARV medicines,’’ with responses on a 4-point Likert scale
(ranging from 1, ‘‘strongly disagree,’’ to 4, ‘‘strongly agree’’).
Mean scores were categorized into high accuracy (if the
score corresponded to ‘‘agree’’ or ‘‘strongly agree’’) and low
accuracy [21].
Enabling factors (i.e. means available to access care)
examined included urban/rural residence; food insecurity;
knowing someone on ART; HIV status disclosure; social support
(9 questions; Cronbach’s alpha0.92, adapted from pre-
vious work by Wortman [22] with questions such as ‘‘Would
someone be available to talk to you if you were upset, nervous
or depressed?’’); and communication barriers with providers
(difficulties understanding information about HIV care or ART
side effects).
Having been tested for HIV because of partner’s sickness,
death or HIV diagnosis was examined within the ‘‘need’’
component of the framework.
Correlates from routine clinical information
CD4 count at enrolment in HIV care was defined as the
earliest recorded CD4 measurement in the first six months
in care. A gap in care was defined as not having had a clinic
visit for at least six months prior to ART initiation. Enrolment
point of entry captured the source of the patient’s referral to
HIV care. Receipt of TB treatment at any point prior to ART
initiation was also recorded.
Statistical methods
We compared the distribution of key sample characteristics
between male and female participants using chi-square and
Mann-Whitney tests of statistical significance. Potential cor-
relates of late ART initiation were examined through bivariate
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and multivariable logistic regression. To assess added informa-
tion on correlates of late ART initiation that may be gained
from psychosocial data, two separate regression models were
constructed using only psychosocial data and then combining
them with routine clinical variables. Multivariable regression
models initially included all variables that had p-values B0.20
in bivariate analyses. Covariateswith the highest p-valueswere
eliminated through backward stepwise regression until all
remaining variables had p-values B0.05. Eliminated variables
were then added individually back to this model in case
of negative confounding (i.e. associations observed only in
the presence of other variables). Sex and age group were
retained in multivariable models in order to produce sex
and age-adjusted odds ratios. Sex-specific models were also
constructed to elucidate possible differences in correlates
by gender. Median CD4 counts at ART initiation were plot-
ted by month and sex to assess the trend over time and
possible impact of expanded guidelines on ART uptake.
Analyses were conducted in SAS 9.3 (SAS Institute, Cary,
NC, USA) using conditional logistic models with clinical sites
as strata.
Ethical considerations
The study was approved by the Institutional Review Boards
of the Oromia Regional Health Bureau, Columbia University
Medical Center and the City University of New York. Written,
informed consent for the interview and extraction of medical
record data was obtained from each patient prior to study
enrolment.
Results
Characteristics of persons initiating ART
The majority of participants were women (61.2%) and the
median age was 34 (interquartile range (IQR): 28 to 40). Most
patients were Ethiopian Orthodox (69.9%), urban residents
(78.0%) and had no more than primary school education
(71.8%). Women were more likely than men to have received
no education (39.1% vs. 20.1%, pB0.001). More than half of
the participants were in a relationship at the time of ART
initiation and a quarter had been widowed. The largest
proportion (55.7%) was first diagnosed with HIV in a PITC
setting (Table 1).
Clinical and immunological characteristics at enrolment and
ART initiation
Of the 97.4% of participants with available CD4 counts and/
or WHO stage at enrolment in HIV care, 27.3% had enrolled in
HIV care with advanced HIV infection (CD4 B150 cells/mL
or WHO Stage IV). The median enrolment CD4 count
among the 94.0% of participants with available data was 263
cells/mL (IQR: 140 to 390), with significantly higher values
among women (median296; IQR: 172 to 423) than men
(median206; IQR: 108 to 344, pB0.001). Overall, 47.8% of
participants were already beyond the point of ART eligibility
at enrolment in HIV care, including 57.9% of men and 41.4%
of women (pB0.001). Median time between enrolment
in care and ART initiation was 2.9 months (IQR: 15 days to
2.6 years). This period was significantly shorter among men
than women (median 1.1 months vs. 5.3 months, respec-
tively; pB0.001). At ART initiation, 31.2% of participants
were classified as having late-stage HIV infection, most of
whom (85.1%) already had advanced HIV disease at enrol-
ment in care. Among the 91.2% of participants with available
data, the median CD4 count at treatment initiation was
212 cells/mL (IQR: 119 to 288) and was significantly higher
among women than men (median232; IQR: 152 to 302; vs.
median178; IQR: 98 to 251, respectively; pB0.001). After
HIV care enrolment and prior to ART initiation, 12.7% of
patients underwent TB treatment (Table 2). Among these
patients, the median delay between initiation of TB treatment
and ART was 27 days (IQR: 14 to 97 days), with 65% starting
ART within eight weeks.
During the study period, there was an appreciable increase
in the median CD4 count at ART initiation. An increase in
CD4 counts was observed among both men (average of
30 cells) and women (average of 78 cells) after the January
2013 guideline expansion (p0.003 and pB0.001, respec-
tively). The proportion of patients starting treatment
with advanced HIV infection decreased significantly, from
40.8% in June 2012 to 22.0% in April 2013 (ptrendB0.001;
Figure 1).
Factors associated with late ART initiation
Table 3 presents bivariate associations, a multivariable model
including only the psychosocial variables and a final multi-
variable model incorporating the clinical variables.
Psychosocial variables
In the final multivariable model, men had twice the odds of
late ART initiation as non-pregnant women (aOR: 2.02; 95%
CI: 1.50 to 2.73). Psychological distress (high vs. low/none,
aOR: 1.96; 95% CI: 1.34 to 2.87) and perceived communica-
tion barriers with providers (vs. no barriers, aOR: 2.42; 95%
CI: 1.24 to 4.75) were associated with increased odds of late
ART initiation, whereas testing for HIV because of a partner’s
death or illness (vs. not, aOR: 0.64; 95% CI: 0.42 to 0.95) was
associated with lower odds. In the multivariable model
containing only psychosocial variables, patients who knew
someone on ART (vs. not, aOR: 0.77; 95% CI: 0.57 to 1.04)
and those who had disclosed their status to two or more
people (vs. 0, aOR: 0.69; 95% CI: 0.46 to 1.02) were also
marginally less likely to initiate treatment with advanced HIV
disease, but these associations were no longer significant
after adjustment for clinical factors.
Clinical variables
Participants referred to HIV care from PITC (vs. VCT, aOR:
1.47; 95% CI: 1.07 to 2.04) and those with history of TB
treatment while in HIV care (vs. no treatment, aOR: 2.16;
95% CI: 1.43 to 3.25) had higher odds of initiating treatment
with advanced HIV infection. Having a gap in pre-ART care of
six months or more was also associated with late ART
initiation (aOR: 2.02; 95% CI: 1.10 to 3.72), as was initiation
in the first six months after enrolment in care (aOR: 8.98;
95% CI: 5.34 to 15.08). Inclusion of the gap in care vari-
able eliminated the disclosure variable from the final model
(Table 3).
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Sex-specific models
When psychosocial and clinical data were analyzed separately
for men and women, sex differences included marginally
lower odds of late ART initiation by men if they had dis-
closed their HIV status to at least two people (vs. none, aOR:
0.61; 95% CI: 0.36 to 1.05) and higher odds of late
ART initiation if referred to HIV care from PITC settings
(vs. VCT, aOR: 1.96; 95% CI: 1.21 to 3.18). In contrast, women
had higher odds of late treatment initiation if they re-
ported experiencing communication barriers with pro-
viders (vs. none, aOR: 2.51; 95% CI: 1.10 to 5.75) (models
not shown).
Table 1. Characteristics of patients initiating ART, by sex, at six Ethiopian clinics (June 2012 to April 2013)
Total
Sample Men Women
n % n % n % pa
Total 1180 100.0 458 38.8 722 61.2 
Sex
Male 458 38.8     
Female, not pregnant 669 56.7    
Female, pregnant 53 4.5    
Age
Median (IQR) 34 (28 to 40) 37 (32 to 43) 30 (26 to 38) B0.001
18 to 29 374 31.7 78 17.0 296 41.0 B0.001
30 to 39 482 40.8 205 44.8 277 38.4
40 to 49 238 20.2 131 28.6 107 14.8
50 86 7.3 44 9.6 42 5.8
Religion
Ethiopian Orthodox 825 69.9 323 70.5 502 69.5 0.549
Protestant 239 20.3 85 18.6 154 21.3
Muslim 108 9.2 47 10.3 61 8.4
Other Christian 8 0.7 3 0.7 5 0.7
Highest education level
No school 374 31.7 92 20.1 282 39.1 B0.001
Primary school or vocational/other 484 41.0 206 45.0 278 38.5
Secondary school 239 20.3 111 24.2 128 17.7
University 83 7.0 49 10.7 34 4.7
Area of residence
Urban area 920 78.0 335 73.1 585 81.0 0.002
Rural area 259 21.9 122 26.6 137 19.0
Unknown 1 0.1 1 0.2 0 0.0
Relationship status
In a relationship 673 57.0 309 67.5 364 50.4 B0.001
Not in a relationship 507 43.0 149 32.5 358 49.6
Ever widowed
Yes 293 24.8 75 16.4 218 30.2 B0.001
No 874 74.1 377 82.3 497 68.8
Unknown 13 1.1 6 1.3 7 1.0
Original diagnosis unit
PITC 647 54.8 245 53.5 402 55.7 0.763
VCT 513 43.5 205 44.8 308 42.6
Unknown 20 1.7 8 1.7 12 1.7
Site
Ambo Hospital 241 20.4 109 23.8 132 18.3 0.027
Bishoftu Hospital 309 26.2 133 29.0 176 24.4
Fitche Hospital 166 14.1 53 11.6 113 15.7
Goba Hospital 129 10.9 45 9.8 84 11.6
Nekemte Hospital 194 16.4 70 15.3 124 17.2
Shashemene Hospital 141 11.9 48 10.5 93 12.9
ART, antiretroviral therapy; IQR, interquartile range; PITC, provider-initiated testing and counselling; VCT, voluntary counselling and testing;
achi-squared test for categorical variables, Mann-Whitney U test for continuous variables.
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Discussion
In our study, conducted with a large sample of patients
initiating ART in a mature national HIV programme in East
Africa, 31.2% of patients started ART with advanced HIV
infection (CD4 B150 cells/mL or WHO Stage IV), of whom
85.1% already had advanced HIV infection at the time of
enrolment in care. This finding underscores the need to
promote and expand testing coverage in the community to
provide opportunities for earlier diagnosis with timely link-
age to care, particularly for men. Additionally, we identified a
number of factors that could represent potentially important
targets for interventions aimed at reducing the persistently
high rates of late ART initiation.
In multivariable analysis, consistent with prior research
[7,14], male sex was a strong correlate of late ART initiation,
with men having twice the odds of starting treatment with
advanced HIV infection as non-pregnant women.This disparity
is increasing over time [7] and has been at least partly
attributed to women’s increasing access to PMTCT services
[23,24], as well as differences in health-seeking behaviour
resulting in delayed diagnosis and care entry among men [25].
Patients with a gap in care of six months or greater prior
to ART initiation had twice the odds of initiating treatment
with advanced HIV infection. This finding is consistent with
the results of a recent large-scale analysis of data from sub-
Saharan Africa conducted by our team [7]. Others have noted
that fewer than a third of patients not eligible for treatment
at the time of enrolment in care are retained in pre-ART
care in the region [26]. In one study conducted in Ethiopia,
those with less advanced HIV infection were more likely to be
lost to follow-up prior to ART initiation than those with
advanced HIV infection [12]. Patients enrolling in care at the
early stages of HIV infection may therefore be more likely
to remain engaged in care where there are services that
Table 2. Clinical and immunological characteristics at enrolment in care and ART initiation at six Ethiopian clinics (June 2012 to April
2013)
Enrolment in care ART initiation
n (%) % among men % among women n (%) % among men % among women
Total 1180 (100) 1180 (100)
Advanced HIV diseasea
Data available 1149 (97.4) 98.0 96.8 1180 (100) 100 100
Yes 313 (27.3) 38.3 20.1 368 (31.2) 43.2 23.6
No 835 (72.7) 61.7 79.9 812 (68.8) 56.7 76.4
CD4 count, cells/mL
Data available 1109 (94.0) 6.1 6.0 1076 (91.2) 93.9 89.5
Median (IQR) 263 (140 to 390) 206 (108 to 344) 296 (172 to 423) 212 (119 to 288) 178 (98 to 251) 232 (152 to 302)
Clinical WHO disease stage
Data available 1136 (96.3) 96.9 95.7 1177 (99.7) 99.8 99.6
Stage I 381 (33.6) 22.5 40.6 257 (21.8) 14.9 26.2
Stage II 307 (27.0) 30.2 25.0 335 (28.5) 28.5 28.5
Stage III 418 (36.8) 43.9 32.2 540 (45.9) 52.7 41.6
Stage IV 30 (2.6) 3.4 2.2 45 (3.8) 3.9 3.8
ART eligibility at enrolmentb
Not eligible 585 (49.6) 40.1 55.5  
Eligible 564 (47.8) 57.9 41.4  
Unknown 31 (2.6) 2.0 3.1  
History of TB treatment in HIV care
Yes   150 (12.7) 15.9 10.7
No   1030 (87.3) 84.1 89.3
Time between diagnosis and ART initiation
Median (IQR) 8.3 months (1.1 months to 3.4 years)
Men 3.6 months (27 days to 2.4 years)
Women 1.1 years (1.2 months to 4 years)
Time between enrolment in care and ART initiation
Median (IQR) 2.9 months (15 days to 2.6 years)
Men 1.1 months (14 days to 1.4 months)
Women 5.3 months (18 days to 3.1 years)
ART, antiretroviral therapy; IQR, interquartile range; TB, tuberculosis; WHO, World Health Organization; aadvanced HIV disease at enrolment or
ART initiation is defined as having a CD4 cell count B150 cells/mL or WHO Stage IV; beligibility based on national Ethiopian HIV guidelines.
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could be perceived as beneficial to them such as free co-
trimoxazole [27] and time-saving clinic-level efficiencies, such
as reliable point-of-care CD4 testing [28].
Additional support may be beneficial for patients under-
going TB treatment in HIV care, who had twice the odds of
late ART initiation as those who did not undergo TB
treatment; an association previously also reported elsewhere
in sub-Saharan Africa [7]. Although TB disease is more
common among persons with advanced HIV-related immu-
nosuppression, both the disease itself and TB therapy can
each be markers of and risk factors for late ART initiation.
TB disease can accelerate CD4 decline [29] and uptake of
treatment guidelines in clinical practice can take time [30].
Although WHO guidelines recommend that TB treatment
be started first, with ART added as soon as possible during
the first eight weeks of TB therapy [17,31], only 65% of TB
patients in our study initiated ART within that period.
Concerns about drug interactions, additional side effects,
immune reconstitution inflammatory syndrome and high
pill burden often cause ART initiation to be delayed until TB
treatment has been completed, despite evidence that inte-
gration of TB and HIV treatment may successfully extend AIDS-
free survival of severely immunocompromised patients [32].
Alongside clinical variables, several psychosocial factors
were identified as significant correlates of late ART initiation.
The marginal association between disclosure of HIV status
to at least two people and lower odds of late ART initiation
suggests that practical and emotional support potentially
enabled by disclosure may facilitate engagement in care and
timely treatment initiation. A similar observation was pre-
viously reported in another Ethiopian study, where non-
disclosure of HIV status was associated with late presentation
to HIV care [10]. Although facilitation of disclosure and testing
of family members, mainly partners, is recognized by HIV
care providers as a critical element of pre-ART care, disclosure
appears to be discussed less frequently with patients after
initial enrolment visits [33], perhaps because most patients
have by then disclosed their status to at least one person.
However, our findings suggest that it may be worthwhile
for clinic staff to continue encouraging disclosure, especially
among men, even after a patient has disclosed to one other
person. That the disclosure variable was eliminated from our
final multivariable model when the gap in care variable
was introduced suggests that time since enrolment in care
partially confounds the association between disclosure and
late ART initiation [34], but also that poor engagement in care
may be one of the ways that under-disclosure influences the
risk of delayed treatment initiation.
Enacted and internalized stigma were not significantly
associated with late ART initiation, consistent with a prior
ecological study from eight sub-Saharan African countries
[35], but in contrast to qualitative research from the region
[15]. Psychological distress, however, previously linked with
late HIV diagnosis [8], was strongly associated with late ART
initiation in our analysis. Although advanced HIV disease may
be a cause of psychological distress, rather than the reverse,
this association suggests that it is important for providers
to screen for signs of distress at enrolment in HIV care and
subsequent clinic visits, with referral to appropriate/available
resources such as peer support or mental health services,
where available.
Problems understanding HIV care providers, reported by
nearly 5% of participants, can constitute a barrier to timely
treatment initiation, especially among women, for whom
this variable remained highly significant in final sex-specific
models. This finding underscores the need for individualized,
stage-appropriate counselling [36], as well as frequent assess-
ments of patient understanding/comprehension during clinic
visits.
The impact of gaps in care on late ART initiation may have
been lessened by the January 2013 expansion of Ethiopia’s
national ART guidelines to include all patients with CD4
counts 5350 [17].We observed a substantial decrease in the
proportion of patients initiating treatment late and an
increase in median CD4 counts at initiation among both
men and women during the study period (June 2012 to April
2013). This finding suggests that the expansion of ART
initiation guidelines enabled the clinics to put more patients
who were already diagnosed and engaged in pre-ART care on
treatment earlier, before their health deteriorated further.
Figure 1. Median CD4 count at antiretroviral therapy (ART) initiation and proportion of patients initiating ART late, by month and sex.
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Table 3. Bivariate and multivariable associations between participants’ characteristics and late ART initiationa
Bivariate
Multivariable Model 1
(N1171)b
Multivariable Model 2
(N1174)c
n OR (95% CI) aOR (95% CI) aOR (95% CI)
Predisposing factors
Sex (ref: non-pregnant women, n669)
Men 458 2.34 (1.81 to 3.03) 2.29 (1.73 to 3.02) 2.02 (1.50 to 2.73)
Pregnant women 53 0.44 (0.19 to 1.00) 0.41 (0.18 to 0.97) 0.53 (0.21 to 1.33)
Age at ART initiation (ref: 18 to 29, n374)
30 to 39 482 1.63 (1.21 to 2.19) 1.27 (0.92 to 1.75) 1.25 (0.88 to 1.77)
40 to 49 238 1.29 (0.90 to 1.85) 0.91 (0.61 to 1.35) 0.92 (0.60 to 1.40)
50 86 1.14 (0.67 to 1.93) 0.72 (0.41 to 1.26) 0.60 (0.33 to 1.10)
Education level (ref: primary school or vocational/other, n484)
No school 374 0.78 (0.57 to 1.05)
Secondary school 239 1.09 (0.78 to 1.51)
University 83 1.16 (0.71 to 1.91)
Relationship status (ref: in a relationship, n673)
Not in a relationship 507 1.15 (0.90 to 1.48)
Has ever had children (ref: no, n253)
Yes 926 0.78 (0.58 to 1.05)
Alcohol use (ref: low or none, n916)
High 162 1.59 (1.12 to 2.26)
Moderate 102 1.06 (0.68 to 1.67)
Psychological distress (ref: low or none, n480)
Medium 348 1.93 (1.41 to 2.66) 1.76 (1.27 to 2.46) 1.61 (1.12 to 2.31)
High 347 2.91 (2.08 to 4.07) 2.70 (1.90 to 3.85) 1.96 (1.34 to 2.87)
Enacted stigma (ref: none, n983)
Any 192 1.05 (0.74 to 1.48)
Internalized stigma (ref: top tercile/least stigma, n469)
Bottom tercile (most stigma) 395 1.44 (1.06 to 1.94)
Middle tercile 310 1.24 (0.90 to 1.70)
History of holy water use for HIV (ref: no, n840)
Yes 189 0.69 (0.48 to 0.99)
Treatment beliefs (ref: low accuracy, n118)
High accuracy 1061 0.86 (0.56 to 1.32)
Enabling factors
Area of residence (ref: rural, n259)
Urban 920 0.79 (0.59 to 1.07)
Trouble satisfying food needs in last year (ref: never, n422)
Sometimes 502 0.91 (0.68 to 1.22)
Often 252 0.84 (0.59 to 1.19)
Knows someone on ART (ref: no, n368)
Yes 809 0.73 (0.56 to 0.95) 0.77 (0.57 to 1.04)
Number of people disclosed to (ref: 0, n167)
1 422 0.79 (0.55 to 1.15) 1.00 (0.67 to 1.49)
]2 591 0.57 (0.40 to 0.82) 0.69 (0.46 to 1.02)
Social support (ref: bottom quarter/least support; n298)
Second quarter 305 0.91 (0.64 to 1.28)
Third quarter 292 0.84 (0.59 to 1.19)
Top quarter ( most support) 285 0.90 (0.62 to 1.30)
Communication barriers with providers (ref: no, n1127)
Yes 53 2.27 (1.30 to 3.97) 2.43 (1.32 to 4.48) 2.42 (1.24 to 4.75)
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Major strengths of the study include the combination of
longitudinal clinical data, including pre-ART care data, dating
back to participants’ enrolment in care with self-reported
information from interviews, as well as a high degree of data
completeness. Our study also has some limitations. The
clinics included in the study may not be representative of
all settings in which Ethiopian patients receive HIV care
and treatment, tempering our ability to further generalize
our findings. A large proportion of persons initiating treat-
ment with late-stage HIV already had advanced infection at
enrolment in HIV care, and likely often at diagnosis, making
it challenging to tease apart the correlates of late ART in-
itiation from factors related to late enrolment or diagnosis.
Additionally, our study did not include those patients who
died prior to ART initiation, who may have had very advanced
HIV disease. Finally, the cross-sectional nature of the inter-
view relative to outcome measurement makes it difficult to
sort out temporality of some exposures measured in the
interviews in relation to the outcome.
Conclusions
A substantial number of patients who initiated ART in our
study already had advanced HIV infection at the time of
enrolment into care, pointing to the need to expand testing
coverage with timely linkage to care. Although the propor-
tion of patients initiating ART late decreased over time in our
study, many patients still started treatment with low CD4
counts (Figure 1). Patient sub-groups (such as men, those
who have not disclosed their HIV status, those experiencing
distress and those reporting communication difficulties with
providers) may be at increased risk of late ART initiation.
Additionally, elements of clinical histories (referral from PITC
settings, gaps in pre-ART care, TB treatment) can be used
by providers to identify patients who may be in need of
targeted support in preparation for retention and timely ART
initiation. Clinic-based programmatic initiatives promoting
patient-centred, stage-appropriate counselling, engagement
in pre-ART care and smoother integration of TB and HIV
treatments may also facilitate more timely ART initiation.
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